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ABSTRACT 
Objective: Identifying new inhibitors of Epidermal Growth Factor Receptor (EGFR) by virtual screening using a pharmacophore model followed by docking.  
Methods: A pharmacophore model was developed using a dataset of 77 chemically diverse EGFR inhibitors using PHASE. Statistically valid Three 
Dimensional Quantitative Structure Activity Relationship (3D-QSAR) equations were generated for the pharmacophore model. This was followed by 
database screening to obtain probable hits. Docking of the probable hits into the crystal structure of EGFR was used as a second filter. Docking 
studies were carried out using GLIDE. Calculation of ADME properties of the probable hits arising out of docking further reduced the number of hits.  
Results: A five-point pharmacophore was generated for EGFR inhibitors reported in literature. The pharmacophore indicated that the presence of 
two aromatic ring features (R), one acceptor feature (A), one donor feature (D) and one hydrophobic feature (H) is necessary for potent inhibitory 
activity. The generated pharmacophore yielded statistically significant 3D-QSAR model, with a correlation coefficient r2 of 0.9905 and q2 of 0.8764. 
Virtual screening using the best pharmacophore model resulted in 372 hits. Docking studies as a second filter reduced the hits to 8. Application of 
drug-likeness as a third filter gave 6 leads. 
Conclusion: 6 leads with satisfactory pharmacokinetics properties were identified as potential EGFR inhibitors. This study may facilitate 
development of some new potential EGFR inhibitors.  
Keywords: EGFR inhibitors, 3D-QSAR, Pharmacophore, Docking, Virtual screening. 
 
INTRODUCTION 
A majority of the therapeutically used anticancer agents are 
associated with a major drawback of being nonspecific and non-
targeted in their action. However, advances in biochemistry and 
molecular biology have lead to identification of an array of pathways 
which are disregulated in cancer [1]. Targeting disregulated 
pathways in an attempt to control cancerous growth is an approach 
which is proposed to be less toxic to the normal cells. The epidermal 
growth factor receptor (EGFR) is a member of the receptor family of 
tyrosine kinases [2]. Receptor tyrosine kinases are involved in a 
range of cancer cell behaviors, including excess growth, invasion and 
blood vessel formation [3]. EGFR is known to be over-expressed in 
several human solid tumors [4]. Therefore, EGFR has received much 
attention as a target for anticancer drugs [5, 6]. Erlotinib, Gefitinib 
and Lapatinib are some of the important drugs belonging to the class 
of EGFR inhibitors in clinical practice [7, 8]. 
Small molecules that inhibit the kinase activity of EGFR are of 
considerable interest as new therapeutic antitumor agents for the 
treatment of EGFR mediated cancers. These molecules act by 
binding, either reversibly or irreversibly, to the C-terminal tyrosine 
kinase domain of EGFR. Anilinoquinazolines are among the most 
explored compounds reported as EGFR inhibitors [9, 10]. These 
compounds, however, may not be very specific for inhibiting EGFR 
mutants because of their size and pattern of H-bonding interaction. 
This calls for exploration of other classes of compounds.  
Pharmacophore modeling is considered as one of the important 
approaches used in the ligand-based drug discovery [11-13]. A 
pharmacophore model is a very useful tool for the screening of the 
database, and if combined with docking at a later stage, it can 
combine an advantages of both ligand-based and structure-based 
approaches for drug discovery. In view of these facts, the present 
study involved development of pharmacophore model, QSAR 
equations and use of these data for the screening of commercially 
available databases in search of novel chemical scaffolds.  
MATERIALS AND METHODS 
Selection of dataset 
A total of 77 EGFR inhibitors (table 1) reported in the literature [14] 
belonging to different chemical classes were used as a dataset for 
present pharmacophore modelling studies. The activity values were 
expressed as pIC50 ranged from 4 to 9 spanning five orders of 
magnitude. The ligands were considered as actives if pIC50 value was 
greater than ≥8.5 and considered as inactives if pIC50 value was ≤ 5. 
This resulted in a set of 23 highly active molecules and 17 inactive 
molecules. The dataset was divided into a training set (54 
compounds) and a test set (23 compounds; table 1). Since the 
usefulness of the QSAR model depends on the diversity of structures 
and on effective spanning of the activity range, training set was 
selected after considering these parameters. The inhibitor, Erlotinib 
(Compound No.3), was also included in the training set. 
 
Table 1: Structures and biological activities of training and test set compounds 
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(T) indicates compounds in test set 
Joshi et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 6, 77-91 
87 
Generation of common pharmacophore hypotheses 
PHASE, version 3.3, Schrodinger, LLC, New York, NY, 2011 
implemented in the Maestro 9.3 software package was used to 
generate pharmacophore and three-dimensional quantitative 
structure–activity relationship (3D-QSAR) models for EGFR 
inhibitors. The two-dimensional (2D) chemical structures of the 
compounds were sketched in Maestro graphical interface and 
converted into corresponding standard three-dimensional (3D) 
structures using the best conformation model generation method 
with OPLS-2005 force field and mixed Monte Carlo multiple 
minimum/low mode (MCMM/lMOD) search algorithm to reduce 
redundant conformers. Conformations with energy higher than the 
global minimum by 10kcal/mol were rejected. Whenever the 
structure contained a chiral carbon, all possible isomers were 
generated for the study.  
A set of six built-in pharmacophoric features including hydrogen-bond 
(H-bond) acceptor (A), H-bond donor (D), hydrophobic group (H), 
hydrophobic aromatic rings (R), positively ionizable group (P) and 
negatively ionisable group (N) are provided in Phase. This set of features 
was used to generate pharmacophoric sites for all the compounds. 
Various pharmacophore hypotheses were generated by taking into 
consideration active compounds using a tree-based partitioning 
technique that groups together similar pharmacophores based on their 
intersite distances. A tree depth of four was used in the present work. 
The terminal box size was 1 A °. The generated hypotheses were 
subjected to a stringent scoring process. The hypotheses which survived 
the scoring process were taken up for building QSAR models. Scoring 
with respect to actives was conducted using default parameters for site, 
vector, and volume terms. 
Building QSAR models 
Phase provides the means to build 3D-QSAR models for a set of ligands 
which are aligned to a selection of hypotheses and to visualize these 
models along with the ligand structures and the hypotheses. The QSAR 
models were developed for ligands belonging to the training set with a 
range of activities. The molecules of the training set were placed in a grid 
box of cubes, with each cube dimension corresponding to 1A °. Each cube 
was allotted a binary number based on the presence or absence of the 
pharmacophoric features present in it. This representation was then 
used to generate a 3D-QSAR model using partial least squares (PLS) 
method. All hypotheses successfully generated and scored were then 
used to build pharmacophore-based 3D-QSAR models with grid spacing 
1A °, random seed value of one, and 5 PLS factors. The quality of the 
generated QSAR models was assessed by examining the associated 
statistical parameters such as standard deviation (SD), root mean square 
error (RMSE), variance ratio (F) and correlation coefficients: r2 and q2. 
Validation of pharmacophore and 3D-QSAR models 
The generated 3D-QSAR models were validated by leave-one-out 
method and prediction of activities of the test set compounds using 
the QSAR model. Result of the QSAR validation was also included as 
criterion for selection of best pharmacophore hypothesis. 
Database screening using pharmacophore hypothesis 
The best pharmacophore hypothesis was used as a 3D query for 
screening ZINC database. The purpose of this screening was to 
retrieve potential hits suitable for further development. Conformers 
were generated for each molecule in the database using Confgen. 
The database screening was carried out using phase virtual 
screening protocol implemented in Schrodinger with Best/Flexible 
Search option. The molecules retrieved from the database mapped 
all the five features of the pharmacophore.  
Molecular docking  
These studies were done using GLIDE (Maestro, version 8.5, 
Schrodinger, LLC, 2008) software and the crystal structure of EGFR 
(PDB code: 1M17), complexed with 4-anilinoquinazoline inhibitor, 
Erlotinib. The crystal structure was cleaned by deleting the ligand 
and the cofactors. This was followed by adding hydrogen atoms in 
their standard geometry, adjusting the bond orders and formal 
charges. The crystal structure was then refined, and the geometries 
were optimized with the OPLS-2005 force field using standard 
protocol and parameters. The inhibitor was extracted from the 
complex and re-docked (fig. 1).  
The final docked conformation of the inhibitor was aligned to the 
original conformation and root mean square deviation (RMSD) 
calculated. RMSD value of 1.12 confirmed the accuracy of the 
docking program. The docking studies were carried out using extra 
precision mode of Glide using default parameters. The active site 
was defined by the generation of a grid box such that the co-
crystallized ligand occupied the center of the box. 
 
 
Fig. 1: Validation of docking protocol by re-docking 1M17 
associated ligand, Erlotinib into the active site of the receptor 
 
All the hits obtained from pharmacophore screening were subjected 
to molecular docking using standard precision mode of Glide which 
gave G-score value corresponding to each compound. The G-score 
value was calculated by taking into consideration the favorable van 
der Waals, coulombic, lipophilic and hydrogen-bonding interactions 
and penalizing for steric and buried polar clashes. Compounds with 
lower G-score were eliminated and the remaining compounds were 
subjected to extra precision docking. This was followed by 
interaction-based selection of 8 hits. 
Qik prop descriptors 
These hits obtained from the database were also subjected to further 
filter via Lipinski’s rule of five to identify compounds with potent 
EGFR inhibitory activity and favorable absorption, distribution, 
metabolism and excretion (ADME) properties. The ADME properties 
were calculated using QikProp. In the present study, QikProp was 
run in normal processing mode with default options. 
RESULTS AND DISCUSSION 
Pharmacophore model 
The active ligands were used to identify common pharmacophore 
hypotheses by following a tree-based partitioning technique that 
groups together similar pharmacophores according to their inter 
site distances. Six top-ranked five featured hypotheses were chosen 
for building QSAR equations (table 2).  
 
Table 2: Summary of phase 3D-QSAR statistical results of six top-ranked hypotheses 
Hypotheses SD r2 F RMSE q2 Pearson-R 
ADHRR.442 0.2491 0.9851 635.1 0.6786 0.7718 0.9206 
ADHRR.256 0.2131 0.9891 871.2 0.7893 0.6913 0.9008 
ADHRR.409 0.1641 0.9935 1475.9 0.6066 0.8177 0.9251 
ADHRR.187 0.1988 0.9905 1002.2 0.4994 0.8764 0.9507 
AADHR.359 0.2043 0.99 948.5 0.5982 0.8227 0.9307 
AAHRR.313 0.1952 0.9909 1040.1 0.6427 0.7954 0.9059 
The very first pharmacophore model for the ATP
inhibitors of EGFR was proposed [15] way back in 1999. This model 
highlights four important structural features, a hydrogen bond 
acceptor, a donor, a hydrophobic site and a ring. The crystal 
structure of EGFR tyrosine kinase domain, along with ATP
competitive inhibitor, 1M17 published later focuses on the acceptor 
forming a hydrogen bond with Met769 along with hydrophobic 
interactions. Other pharmacophores reported in the literature for 
EGFR inhibitors include AADHR reported for the class of 
phenylureas [16], AAADRR for pyrrolopyrimidines [1
for a diverse class containing anilinoquinazolines, 
thienopyrimidines [18]. All these pharmacophores 
importance of an acceptor and a ring structure apart from other 
hydrophobic interactions. 
3D-QSAR results 
With known experimental activities, a 3D-QSAR model was created 
for each hypothesis, using ligands that are aligned 
 
Fig. 2: Scatter plot for the predicted activity and actual activity values for EGFR inhibitors in 
 
The best predictive five featured hypothesis (ADHRR.187) 
developed in the present study consisted of one hydrogen
acceptor, one hydrogen-bond donor, one hydrophobic feature (
and two aromatic ring features. The pharmacophore hypothesis and 
inter-site distances between the pharmacophoric sites is depicted in 
fig. 3 and shown in table 3.  
 
Fig. 3: Intersite distance (Å) in the geometry of the 
pharmacophore hypothesis (ADHRR.187).
vectors represent acceptor feature, blue spheres 
represent donor feature, green spheres represent hydrophobic 
feature and orange rings represent aromatic feature
 
When the highest active compound was mapped on the generated 
hypothesis (fig. 4), the quinazoline nitrogen mapped on the acceptor 
feature, secondary amine nitrogen mapped on the donor whereas 
Fluorine mapped on the hydrophobic feature. A benzene 
quinazoline ring was mapped on the ring residues.




7] and AHHHR 
thiazolo and 
highlight the 
to the associated 
pharmacophore on five points. Since the dataset 
significant diversity, a pharmacophore
developed which considered the sites on a molecule that is matched 
to the hypothesis. Statistical validity and robustness of the QSAR 
models can be evaluated using various parameters including SD, F, 
Pearson-R, r2 values of the training set and q
We started the evaluation of QSAR equations with a look at SD, r
and F values. These values are associated with training set results
Table 2 shows six pharmacophore hypotheses which indicated 
satisfactory results of the training sets.
which are associated with the test 
in the next step. A stringent criterion of 
and q2 values of less than or equal to 0.2 was applied to filter the 
hypotheses further. This resulted in 
ADHRR.256. The final filter of RMSE value 
pharmacophore model, ADHRR.187
predicted activity versus actual activity for training and test set, 
respectively, based on the best hypothesis ADHRR.187.
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Table 3: Distances of all pharmacophore hypothesis 
QSAR model 












Fig. 4: Top ranked pharmacophore model mapped on the 
highest active compound (Compound 91)
 Pharm Sci, Vol 7, Issue 6, 77-91 
88 
consists of 
-based 3D-QSAR model was 
2 values of the test sets. 
2 
. 
 Pearson-R and q2values, 
set, were taken into consideration 
the difference between r2 
an elimination of hypothesis 
less than 0.5 gave the best 



















Joshi et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 6, 77-91 
89 
Database screening and docking 
The generated pharmacophore hypothesis was used as a 3D querry 
for searching the ZINC database. This resulted in identification of 
372 hits from the ZINC database. Docking was used as a second filter 
to arrive at probable hits. 
To validate the docking protocol, Docking began with redocking of the 
inhibitor from the co-crystallized ligand. The RMSD between the 
docked pose and the crystallized pose of the same ligand was found to 
be 1.12, thus validating the docking protocol. This was followed by 
docking of the hits obtained using pharmacophore screening into the 
crystal structure of EGFR (PDB code: 1M17). The criteria for selection 
of best 10 compounds out of the 372 hits were based on obtaining a 
good dock score (>7.0) along with the docked structure retaining most 
of the important interactions which are seen in the crystal structure. 
Hydrogen bonding interaction with Met769 was defined as the most 
important interaction [19] and the hits in which this interaction was 
absent were rejected. The procedure gave eight compounds which 
fitted in these criteria. Fig. 5 shows structures of the identified 
compounds from ZINC database and fig. 6 shows the docked images of 
the same. Table 4 shows interaction of these eight compounds with the 
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Fig. 6: Two dimensional representations of lead molecules in their binding orientation in the active site of EGFR 
 
Table 4: Summary of docking results for 8 leads 
Compounda Glide score Interacting residues 
ZINC44012931 -7.86 Met769, Leu768, Gly772, Leu694, Leu820, Pro770, Ala719, Ile720, Ile765 
ZINC32650290 -7.20 Met769, Leu768, Gly772, Leu694, Leu820, Pro770, Ala719, Ile720, Ile765, Ile753 
ZINC32544573 -8.54 Met769, Asp831, Leu768, Gly772, Leu694, Leu820, Pro770, Ala719, Ile720, Ile765, Leu753 
ZINC017025205 -9.22 Met769, Asp831, Lys721, Thr830, Leu768, Gly772, Leu694, Leu820, Pro770, Ala719 
ZINC04822304 -9.48 Met769, Glu738, Thr766, Leu768, Gly772, Leu694, Leu820, Pro770, Ala719 
ZINC01680588 -9.94 Met769, Asp831, Thr766, Leu768, Gly772, Leu694, Leu820, Pro770, Ala719 
ZINC00611711 -7.16 Met769, Leu768, Gly772, Leu694, Leu820, Leu753, Pro770, Ala719, Ile720, Ile765 
ZINC12804309 -7.03 Met769, Leu768, Gly772, Leu694, Pro770, Ala719 
aLigand Ids for ZINC database 
 
Qik Prop descriptors 
To assess drug likeness of the identified compounds, these 
compounds were subjected to calculation of a variety of ADME 
properties. These included partition coefficient, water solubility, 
percent human oral absorption, permeation through the blood brain 
barrier, and cell permeability. The results as listed in table 5 indicate 
that compounds ZINC04822304 and ZINC01680588 show a 
significantly lower oral absorption. These compounds belong to the 
class of pyrrolopyrimidine and imidazopyrimidine respectively. Both 
these compounds contain a free amino group in their structures. The 
other identified hits belong to chemical classes of chalcone, 
pyrazolopyrimidine, anilinoquinazoline, imidazopyrimidine-2,4-
dione and benzofuranopyrimidine. 
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Table 5: ADME properties of the 8 lead molecules by using QikProp 
Compounda QPlogPo/wb QPlogSc QPlogBBd QPPCacoe QPPMDCKf % human oral absorptiong 
ZINC44012931 2.935 -3.181 -0.157 1995.746 2639.456 100 
ZINC32650290 3.273 -4.391 -0.123 2456.422 1306.837 100 
ZINC32544573 2.664 -4.842 -0.694 968.785 478.039 95.992 
ZINC017025205 -0.241 -1.949 -0.982 305.972 236.556 70.025 
ZINC04822304 -1.082 -2.127 -1.901 43.63 21.247 49.956 
ZINC01680588 -0.469 -2.402 -1.433 94.18 94.17 59.53 
ZINC00611711 0.62 -3.137 -1.328 173.587 74.535 70.658 
ZINC12804309 4.484 -5.399 0.306 5457.062 3096.815 100 
aZINC database ligand IDs, bPredicted octanol/water partition co-efficient log p (acceptable range: −2.0 to 6.5), cPredicted aqueous solubility; S in 
mol/l (acceptable range: −6.5 to 0.5), dPredicted BBB permeability (acceptable range: −3 to 1.2), ePredicted Caco-2 cell permeability in nm/s 
(acceptable range: <25 is poor and>500 is great), fPredicted apparent MDCK cell permeability in nm/s (acceptable range: <25 is poor and>500 is 
great), gPercentage of human oral absorption (<25% is poor and>80% is high). 
 
CONCLUSION 
In conclusion, we have developed a pharmacophore model for ATP-
competitive inhibitors of EGFR, using a diverse set of ligands. A 
QSAR model was developed using this pharmacophore hypothesis. 
The development of the pharmacophore model and QSAR model 
involved use of stringent statistical criteria coupled with knowledge 
of the structure of the receptor. This was then used for screening the 
ZINC database to obtain probable hits. The hits were further filtered 
by docking and calculation of ADME properties to arrive at six 
molecules with probable EGFR inhibitory activity.  
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